Key Metrics
CiteScore 

1.8
H-Index 

53
Impact Factor 

< 5
SJR 

Q2Pharmacology

SNIP 

0.98
Recommended pre-submission checks
Powered by 

Topics Covered on Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS INC |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1991 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Journal of Biopharmaceutical Statistics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Journal of Biopharmaceutical Statistics
Handling missing data using multiple imputation in hybrid control clinical trials with modified power prior
- 8 Aug 2026
- Journal of Biopharmaceutical Statistics
Randomization-based covariance analysis for hypothesis testing of treatment comparisons based on restricted mean survival time with categorized time-to-event data
- 7 Aug 2026
- Journal of Biopharmaceutical Statistics
A phase II, seamless single-arm to two-arm Bayesian design for a time-to-event endpoint
- 1 Aug 2026
- Journal of Biopharmaceutical Statistics
Balancing sample size and accuracy of dose selection in phase 1 oncology trials – designs tiered by cohort size and maximum number of patients treated per dose
- 27 Jul 2026
- Journal of Biopharmaceutical Statistics
Industrialization of Bayesian decision-making for proof-of-commercial-concept study designs
- 25 Jul 2026
- Journal of Biopharmaceutical Statistics
Why the minimum effective dose is unidentifiable – and how a DOR→OOD standard delivers label-ready dosing in oncology
- 25 Jul 2026
- Journal of Biopharmaceutical Statistics
Handling missing data using multiple imputation in hybrid control clinical trials with modified power prior
- 8 Aug 2026
- Journal of Biopharmaceutical Statistics
Randomization-based covariance analysis for hypothesis testing of treatment comparisons based on restricted mean survival time with categorized time-to-event data
- 7 Aug 2026
- Journal of Biopharmaceutical Statistics
A phase II, seamless single-arm to two-arm Bayesian design for a time-to-event endpoint
- 1 Aug 2026
- Journal of Biopharmaceutical Statistics
Balancing sample size and accuracy of dose selection in phase 1 oncology trials – designs tiered by cohort size and maximum number of patients treated per dose
- 27 Jul 2026
- Journal of Biopharmaceutical Statistics
Industrialization of Bayesian decision-making for proof-of-commercial-concept study designs
- 25 Jul 2026
- Journal of Biopharmaceutical Statistics
Why the minimum effective dose is unidentifiable – and how a DOR→OOD standard delivers label-ready dosing in oncology
- 25 Jul 2026
- Journal of Biopharmaceutical Statistics